Inhibition of microRNA-33b specifically ameliorates abdominal aortic aneurysm formation via suppression of inflammatory pathways.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
14 07 2022
14 07 2022
Historique:
received:
27
02
2022
accepted:
04
07
2022
entrez:
14
7
2022
pubmed:
15
7
2022
medline:
19
7
2022
Statut:
epublish
Résumé
Abdominal aortic aneurysm (AAA) is a lethal disease, but no beneficial therapeutic agents have been established to date. Previously, we found that AAA formation is suppressed in microRNA (miR)-33-deficient mice compared with wild-type mice. Mice have only one miR-33, but humans have two miR-33 s, miR-33a and miR-33b. The data so far strongly support that inhibiting miR-33a or miR-33b will be a new strategy to treat AAA. We produced two specific anti-microRNA oligonucleotides (AMOs) that may inhibit miR-33a and miR-33b, respectively. In vitro studies showed that the AMO against miR-33b was more effective; therefore, we examined the in vivo effects of this AMO in a calcium chloride (CaCl
Identifiants
pubmed: 35835906
doi: 10.1038/s41598-022-16017-5
pii: 10.1038/s41598-022-16017-5
pmc: PMC9283493
doi:
Substances chimiques
Antagomirs
0
MicroRNAs
0
Mirn33 microRNA, mouse
0
Calcium Chloride
M4I0D6VV5M
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
11984Informations de copyright
© 2022. The Author(s).
Références
J Vasc Surg. 2010 Jul;52(1):1-4
pubmed: 20494541
Sci Rep. 2014 Jun 16;4:5312
pubmed: 24931346
Arterioscler Thromb Vasc Biol. 2008 Nov;28(11):2071-7
pubmed: 18617650
Arterioscler Thromb Vasc Biol. 2004 Mar;24(3):429-34
pubmed: 14739119
Cell Metab. 2017 Feb 7;25(2):412-427
pubmed: 28041958
Nat Med. 2009 Jun;15(6):649-56
pubmed: 19430489
J Vasc Surg. 2016 Aug;64(2):297-305
pubmed: 27146791
Science. 2014 Aug 8;345(6197):679-84
pubmed: 25104388
Trends Pharmacol Sci. 2021 Jul;42(7):588-604
pubmed: 34020790
J Leukoc Biol. 2002 Jun;71(6):1012-8
pubmed: 12050187
Nat Med. 2019 Feb;25(2):225-228
pubmed: 30559420
N Engl J Med. 2020 Apr 16;382(16):1507-1519
pubmed: 32187462
J Atheroscler Thromb. 2005;12(3):138-42
pubmed: 16020913
Mol Biosyst. 2017 Jan 31;13(2):235-245
pubmed: 27827481
J Am Heart Assoc. 2019 Jul 2;8(13):e012609
pubmed: 31242815
Int J Mol Sci. 2020 Sep 30;21(19):
pubmed: 33008131
Circulation. 2004 Jul 6;110(1):16-21
pubmed: 15210603
N Engl J Med. 2019 Oct 24;381(17):1644-1652
pubmed: 31597037
Nat Rev Drug Discov. 2021 Jun;20(6):427-453
pubmed: 33762737
Int Angiol. 1999 Mar;18(1):52-7
pubmed: 10392481
Org Biomol Chem. 2015 Mar 28;13(12):3757-65
pubmed: 25690587
Circ Res. 2004 Oct 15;95(8):764-72
pubmed: 15486323
N Engl J Med. 2017 Nov 2;377(18):1723-1732
pubmed: 29091570
J Clin Lipidol. 2021 Jul-Aug;15(4):556-568
pubmed: 34172393
Cell Metab. 2011 May 4;13(5):540-9
pubmed: 21531336
N Engl J Med. 2020 Apr 16;382(16):1520-1530
pubmed: 32197277
Nat Immunol. 2016 Jun;17(6):677-86
pubmed: 27089382
Chembiochem. 2012 Nov 26;13(17):2513-6
pubmed: 23081931
J Vasc Surg. 1994 Apr;19(4):727-31
pubmed: 7909340
J Clin Lipidol. 2015 Mar-Apr;9(2):129-69
pubmed: 25911072
J Clin Invest. 2015 Oct 26;125(12):4334-48
pubmed: 26517695
Ann Intern Med. 2020 Aug 18;173(4):JC18
pubmed: 32805173
J Vasc Surg. 2017 Jul;66(1):232-242.e4
pubmed: 28274752
J Lipid Res. 2009 Feb;50(2):204-13
pubmed: 18812596
Circ Res. 2013 May 24;112(11):1456-65
pubmed: 23572498
Circulation. 2015 Aug 18;132(7):578-85
pubmed: 26085454
Circ Res. 2021 Apr 16;128(8):1122-1138
pubmed: 33593073
Circulation. 2008 Oct 28;118(18):1837-47
pubmed: 18852364
Arterioscler Thromb Vasc Biol. 2017 Nov;37(11):2161-2170
pubmed: 28882868
Arterioscler Thromb Vasc Biol. 2017 Nov;37(11):2171-2181
pubmed: 28912363
Nat Commun. 2013;4:2883
pubmed: 24300912
J Clin Invest. 2000 Jun;105(11):1605-12
pubmed: 10841519